A Combined Gas-Phase Separation Strategy for ADP-ribosylated Peptides
Journal of the American Society for Mass Spectrometry · 04.10.2023 · 34 (10) · 2136-2145
DOI: 10.1021/jasms.3c00129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society for Mass Spectrometry, online erschienen am 17.08.2023. Verfasst von Taku Kasai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harv…. Hauptthemen laut MEDLINE: Peptides, Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, U.S. Department of Health and Human Services, Kowa Company Ltd.
Abstract (Originalsprache)
ADP-ribosylation (ADPr) is a post-translational modification that is best studied using mass spectrometry. Method developments that are permissive with low inputs or baseline levels of protein ribosylation represent the next frontier in the field. High-field asymmetric waveform ion mobility spectrometry (FAIMS) reduces peptide complexity in the gas phase, providing a means to achieve maximal ADPr peptide sequencing depth. We therefore investigated the extent to which FAIMS with or without traditional gas-phase fractionation-separation (GPS) can increase the number of ADPr peptides. We examined ADPr peptides enriched from mouse spleens. We gleaned additional insight by also reporting findings from the corresponding non-ADPr peptide contaminants and the peptide inputs for ADPr peptide enrichment. At increasingly higher negative compensation voltages, ADPr peptides were more stable, whereas the non-ADPr peptides were filtered out. A combination of 3 GPS survey scans, each with 8 compensation voltages, resulted in 790 high-confidence ADPr peptides, compared to 90 with GPS alone. A simplified acquisition strategy requiring only two injections corresponding to two MS1 scan ranges coupled to optimized compensation voltage settings provided 402 ADPr peptides corresponding to 234 ADPr proteins. We conclude that our combined GPS strategy is a valuable addition to any ADP-ribosylome workflow. The data are available via ProteomeXchange with identifier PXD040898.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
- Thermo Fisher Scientific (Bremen) GmbH, 28199, Bremen, Germany.
- Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States.
ORCID-Profile: Taku Kasai, Sasha A Singh
Förderung
- NHLBI NIH HHS
- U.S. Department of Health and Human Services
- Kowa Company Ltd
Zitieren
APA
Kasai, T., Kuraoka, S., Higashi, H., Delanghe, B., Aikawa, M., & Singh, S. A. (2023). A Combined Gas-Phase Separation Strategy for ADP-ribosylated Peptides. Journal of the American Society for Mass Spectrometry, 34(10), 2136-2145. https://doi.org/10.1021/jasms.3c00129
Vancouver
Kasai T, Kuraoka S, Higashi H, Delanghe B, Aikawa M, Singh SA. A Combined Gas-Phase Separation Strategy for ADP-ribosylated Peptides. Journal of the American Society for Mass Spectrometry. 2023;34(10):2136-2145. doi:10.1021/jasms.3c00129
BibTeX
@article{Kasai2023,
author = {Kasai, Taku and Kuraoka, Shiori and Higashi, Hideyuki and Delanghe, Bernard and Aikawa, Masanori and Singh, Sasha A},
title = {A Combined Gas-Phase Separation Strategy for ADP-ribosylated Peptides},
journal = {Journal of the American Society for Mass Spectrometry},
year = {2023},
volume = {34},
number = {10},
pages = {2136--2145},
doi = {10.1021/jasms.3c00129}
}
EUVIMED